Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D H Ho

Showing results (21-30 of 117) with videos related to

Pageof 12
Sort By:
CA: a Cancer Journal for Clinicians|July 1, 1973
L-asparaginase for the treatment of cancerK B McCredie, D H Ho, E J Freireich
Antimicrobial Agents and Chemotherapy|December 1, 1981
Comparison of vancomycin disposition in rats with normal and abnormal renal functionsM S Engineer, D H Ho, G P Bodey
Cancer Treatment Reports|January 1, 1982
Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the ratV B Grossie, D H Ho, T L Loo
Acta Physiologica (Oxford, England)|December 17, 2013
A mechanistic look at the effects of adversity early in life on cardiovascular disease risk during adulthoodA S Loria, D H Ho, J S Pollock
Biochemical Pharmacology|January 1, 1972
In vitro-in vivo correlation of drug metabolism--deamination of 1- -D-arabinofuranosylcytosineR L Dedrick, D D Forrester, D H Ho
Biochemistry|January 13, 2000
Factor XI binding to activated platelets is mediated by residues R(250), K(255), F(260), and Q(263) within the apple 3 domainD H Ho, F A Baglia, P N Walsh
Leukemia & Lymphoma|January 1, 1993
L-asparaginase and PEG asparaginase--past, present, and futureM J Keating, R Holmes, S Lerner, et al.
Cancer Investigation|April 29, 1998
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day scheduleR Pazdur, Y Lassere, E Diaz-Canton, et al.
Clinical Pharmacology and Therapeutics|May 1, 1970
Clinical pharmacologic studies of L-asparaginaseD H Ho, B Thetford, C J Carter, et al.
Chemotherapy|January 1, 1988
In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patientsK Rolston, D H Ho, B LeBlanc, et al.
Pageof 12

Showing results (21-30 of 117) with videos related to

Sort By:
Pageof 12
CA: a Cancer Journal for Clinicians|July 1, 1973
L-asparaginase for the treatment of cancerK B McCredie, D H Ho, E J Freireich
Antimicrobial Agents and Chemotherapy|December 1, 1981
Comparison of vancomycin disposition in rats with normal and abnormal renal functionsM S Engineer, D H Ho, G P Bodey
Cancer Treatment Reports|January 1, 1982
Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the ratV B Grossie, D H Ho, T L Loo
Acta Physiologica (Oxford, England)|December 17, 2013
A mechanistic look at the effects of adversity early in life on cardiovascular disease risk during adulthoodA S Loria, D H Ho, J S Pollock
Biochemical Pharmacology|January 1, 1972
In vitro-in vivo correlation of drug metabolism--deamination of 1- -D-arabinofuranosylcytosineR L Dedrick, D D Forrester, D H Ho
Biochemistry|January 13, 2000
Factor XI binding to activated platelets is mediated by residues R(250), K(255), F(260), and Q(263) within the apple 3 domainD H Ho, F A Baglia, P N Walsh
Leukemia & Lymphoma|January 1, 1993
L-asparaginase and PEG asparaginase--past, present, and futureM J Keating, R Holmes, S Lerner, et al.
Cancer Investigation|April 29, 1998
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day scheduleR Pazdur, Y Lassere, E Diaz-Canton, et al.
Clinical Pharmacology and Therapeutics|May 1, 1970
Clinical pharmacologic studies of L-asparaginaseD H Ho, B Thetford, C J Carter, et al.
Chemotherapy|January 1, 1988
In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patientsK Rolston, D H Ho, B LeBlanc, et al.
Pageof 12